A health insurance company has reversed a decision that denied life-changing gene therapy to a 10-year-old boy after his brother was approved treatment for the same genetic disorder.
Noah, 9, and Hunter, 10, both have Duchenne muscular dystrophy (DMD), which weakens the muscles, including the heart. Life expectancy ranges from 30 to 40 years old. Last November, Blue Cross Blue Shield approved a novel gene therapy for Noah, which has seen him thrive. A few months later, the company denied coverage to Hunter.
